The Trulicity lawsuit is not one case but thousands of individual claims against Eli Lilly, consolidated for pretrial handling in a federal multidistrict litigation in Philadelphia. Plaintiffs say the type 2 diabetes drug caused severe gastrointestinal injuries, including gastroparesis, intestinal blockages, and pancreatitis, and that Eli Lilly’s warnings understated the risks. As of mid-2026, no cases have settled and none have gone to trial.1Motley Rice. Trulicity Lawsuit
What Plaintiffs Are Claiming
The lawsuits rest on a failure-to-warn theory. Plaintiffs say Eli Lilly knew or should have known Trulicity could cause serious gastrointestinal harm and did not give patients or prescribers adequate information about those risks.2U.S. District Court, Eastern District of Pennsylvania. MDL 3094 — In Re: GLP-1 RAs Products Liability Litigation (GI Injuries) The master complaint says defendants “downplayed the nature, duration, extent and seriousness of gastrointestinal events” and that the drug labels “were inadequate at all relevant times from launch to present.”3ClassAction.org. GLP-1 RAs Products Liability Litigation — Master Long Form Complaint
Plaintiffs also accuse Eli Lilly of marketing misrepresentation, arguing that aggressive advertising framed GLP-1 drugs as near-miracle treatments while minimizing how severe and prolonged the side effects could be.4ClassAction.org. Lawsuits Claim Novo Nordisk, Eli Lilly Failed to Properly Disclose Debilitating Side Effects of GLP-1 Weight Loss Drugs
Eli Lilly denies the allegations. The company has said patient safety is its “top priority” and that its medications carry “robust, FDA-approved warnings.”5The Indiana Lawyer. More Than Two Dozen Indiana Patients File Lawsuits Against Lilly Over Side Effects of Obesity Drugs
Injuries That May Qualify for a Claim
The gastrointestinal injuries driving most of the litigation are:
- Gastroparesis, or stomach paralysis, where the stomach fails to empty normally, producing chronic nausea, vomiting of undigested food, and malnutrition.
- Intestinal obstruction and ileus, blockages that stop food and waste from moving through the intestines.
- Pancreatitis, sudden inflammation of the pancreas that can become chronic or life-threatening.
- Acute kidney injury, often tied to severe dehydration from persistent vomiting and diarrhea.
- Gallbladder disease, including gallstones, inflammation, and surgical removal.
Plaintiffs’ counsel have estimated that more than 95% of future claims will involve gastroparesis.6U.S. District Court, Eastern District of Pennsylvania. Memorandum on Cross-Cutting Issue No. 1 — Rule 702 Motions
Vision loss claims involving non-arteritic anterior ischemic optic neuropathy (NAION), a sudden and irreversible optic nerve injury, are handled in a separate proceeding, MDL 3163, also assigned to the Eastern District of Pennsylvania. Patients who experienced both gastrointestinal injury and vision loss may have claims in both.7Wagstaff and Cartmell. GLP-1 Multidistrict Litigation (MDL 3094) — What Injured Patients Need to Know in 2026 A parallel New Jersey state proceeding for NAION claims was established in November 2025 before Bergen County Superior Court Judge Gregg A. Padovano.8Pintas & Mullins Law Firm. Separate Litigation Created for NAION Injuries Caused by GLP-1 Drugs
Where the Cases Are Being Heard
Most Trulicity cases sit inside MDL 3094, formally In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation. The Judicial Panel on Multidistrict Litigation created it on February 2, 2024, centralizing pretrial proceedings in the Eastern District of Pennsylvania under Judge Karen Spencer Marston.9U.S. Judicial Panel on Multidistrict Litigation. MDL 3094 Transfer Order The MDL also covers other GLP-1 drugs that share Trulicity’s mechanism: Novo Nordisk’s Ozempic, Wegovy, and Rybelsus, and Eli Lilly’s Mounjaro and Zepbound.2U.S. District Court, Eastern District of Pennsylvania. MDL 3094 — In Re: GLP-1 RAs Products Liability Litigation (GI Injuries)
The caseload has grown fast. The MDL started with about 111 pending actions in mid-2024, exceeded 1,300 by January 2025, surpassed 2,400 by mid-2025, and stood at more than 4,700 civil actions by April 2026.7Wagstaff and Cartmell. GLP-1 Multidistrict Litigation (MDL 3094) — What Injured Patients Need to Know in 2026 Plaintiffs’ counsel estimate the total could eventually exceed 10,000.1Motley Rice. Trulicity Lawsuit
A separate track of Trulicity cases is proceeding in Marion County, Indiana, where Eli Lilly is headquartered. By August 2025, roughly 40 lawsuits had been filed in Marion Superior Court. All name Eli Lilly, and 17 also name Novo Nordisk. Plaintiffs, represented by Edward Mulligan and Jonathon Knoll of CohenMalad LLP, report gastroparesis, debilitating vomiting, abdominal pain, dehydration, and hospitalizations, and seek compensatory and punitive damages.10WFYI News. Marion County Lawsuits Allege Side Effects of Weight Loss Drugs Were Downplayed by Drug Companies11Ink Free News. Indiana Lawsuits Accuse Lilly of Downplaying Obesity Drug Side Effects These cases are proceeding independently of the federal MDL.
Why This Is Not a Class Action
A common misunderstanding is that Trulicity patients are part of a class action. They are not. Each plaintiff files an individual lawsuit, keeps their own attorney, and can receive a separate verdict or settlement tied to their own injuries.1Motley Rice. Trulicity Lawsuit The MDL only consolidates the pretrial phase, so shared issues like discovery, expert qualification, and preemption get resolved once rather than in thousands of courtrooms. Cases that don’t settle after pretrial are typically sent back to their original federal courts for trial.
Where the Litigation Stands
Two threshold fights are shaping everything else.
The first is how gastroparesis gets diagnosed. Defendants argue a reliable diagnosis requires a gastric emptying study, an objective test. Plaintiffs’ experts counter that for drug-induced gastroparesis, physicians can diagnose reliably from patient history, symptoms, and whether symptoms improved after stopping the drug. The court held an evidentiary hearing on May 14, 2025, and issued a detailed memorandum on August 15, 2025, analyzing the competing expert opinions.6U.S. District Court, Eastern District of Pennsylvania. Memorandum on Cross-Cutting Issue No. 1 — Rule 702 Motions How this question is resolved could narrow or widen the eligible pool of plaintiffs sharply.
The second is federal preemption. Eli Lilly argues that because the FDA approved Trulicity’s warning labels, state law cannot impose additional duties to warn. The court bifurcated early discovery to address preemption and warning adequacy first, with discovery into marketing campaigns deferred until after preemption and the learned intermediary doctrine are resolved.12U.S. District Court, Eastern District of Pennsylvania. MDL 3094 — Memorandum on Motion for Reconsideration
In January 2026, the court entered Case Management Order No. 30, setting the path toward selecting bellwether cases and setting deadlines for expert disclosures and briefing.7Wagstaff and Cartmell. GLP-1 Multidistrict Litigation (MDL 3094) — What Injured Patients Need to Know in 2026 No bellwether trial date has been set; the court must first resolve the expert challenges and scientific disputes. Monthly status conferences are scheduled throughout 2026.13U.S. District Court, Eastern District of Pennsylvania. Amended Scheduling Order — 2026 Monthly Conferences
Settlements and What Cases Might Be Worth
No Trulicity lawsuits have settled, and Eli Lilly has not announced a settlement program.1Motley Rice. Trulicity Lawsuit Without trial verdicts or settlement benchmarks, any dollar figures are speculative.
Some legal analysts have published projections based on severity tiers from past pharmaceutical mass torts. One widely cited set of estimates places serious-injury cases (permanent gastroparesis, feeding tubes, or surgery) in the $300,000 to $1,000,000-plus range, moderate cases (hospitalization and chronic symptoms) at $100,000 to $300,000, and lower-tier cases (emergency room visits and temporary symptoms) at $25,000 to $100,000. In pharmaceutical mass torts, settlement talks typically accelerate after bellwether trials produce verdicts, and those trials have not happened in this MDL.
The Label History Behind the Claims
Trulicity was approved by the FDA in 2014 for type 2 diabetes.14U.S. Food and Drug Administration. Trulicity (Dulaglutide) Prescribing Information — 2026 Like other GLP-1 agonists, it works in part by slowing gastric emptying, the same mechanism the lawsuits identify as the source of the alleged injuries. The label’s evolution matters because plaintiffs’ core theory is that warnings lagged behind what Eli Lilly knew.
The most recent label, updated in March 2026, carries a “Severe Gastrointestinal Adverse Reactions” warning that was revised in November 2024. It now lists postmarketing reports of acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, and severe constipation including fecal impaction. The label states that Trulicity “is not recommended in patients with severe gastroparesis,” and warns that acute kidney injury, sometimes requiring dialysis, has been reported in connection with dehydration from severe gastrointestinal reactions.14U.S. Food and Drug Administration. Trulicity (Dulaglutide) Prescribing Information — 2026
The November 2024 update also added warnings about pulmonary aspiration during general anesthesia or deep sedation, linked to delayed gastric emptying.15U.S. Food and Drug Administration. Trulicity (Dulaglutide) Prescribing Information — 2025 The FDA also required a postmarketing study on how temporarily stopping GLP-1 drugs and fasting affects retained stomach contents before surgery.16U.S. Food and Drug Administration. Potential Signals of Serious Risks — New Safety Information Identified by the FDA Adverse Event Reporting System Plaintiffs argue the warnings came too late and remained too soft for years. Eli Lilly maintains its labels complied with FDA requirements throughout.
What the Safety Data Shows
The scientific record is mixed. Clinical trials showed common GI side effects like nausea, vomiting, and diarrhea were dose-dependent and generally mild to moderate. In the AWARD-11 phase 3 trial of 1,842 patients, severe nausea, vomiting, or diarrhea occurred in 0.6% or fewer of patients, and most GI symptoms peaked after starting the drug and declined over time.17National Library of Medicine. Post Hoc Analysis of GI Tolerability of Dulaglutide — AWARD-11 Phase 3 Trial
Postmarketing surveillance looks different. A 2026 analysis of over 412,000 FDA adverse event reports found a statistically significant gastroparesis signal for dulaglutide, with 1,600 gastroparesis reports and a reporting odds ratio of 38.4, meaning gastroparesis was reported far more often in Trulicity users than would be expected by chance.18ResearchGate. Comparative Post-Marketing Pharmacovigilance of Five GLP-1 Receptor Agonists A separate FAERS analysis covering 2007 through 2023 found that dulaglutide was associated with fewer significant GI adverse events than semaglutide, the active ingredient in Ozempic and Wegovy.19National Library of Medicine. GI Adverse Events of GLP-1 RAs — FAERS Database Analysis
Researchers caution that adverse event reports are signals, not proof of causation. For the litigation, though, the volume of these reports and when they appeared in the FDA’s database are likely to be central evidence on what Eli Lilly knew and when.